MINNEAPOLIS, Jan. 24,
2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
TECH) had the honor of welcoming presentations from leading
scientists from two major biopharmaceutical companies, Pfizer and
Sanofi, at the WCBP conference held in Washington D.C. The focus of these
presentations was on the transformative impact of Bio-Techne's
MauriceFlex™ system on their biotherapeutic development processes.
MauriceFlex™, known for its automated capillary isoelectric
focusing (icIEF), also enables protein charge fractionation,
allowing charge variant characterization in downstream analytics
like mass spectrometry. Like the Maurice™ system, the MauriceFlex™
also allows protein size analysis with capillary electrophoresis
sodium dodecyl sulfate (CE-SDS).
Traditionally, the characterization of charge species in
biotherapeutics has faced significant challenges owing to the
limitations in analytical tools, resulting in the use of
time-consuming and laborious methods for isolating individual
variants. Consequently, charge variant characterization has been a
pain point in biotherapeutic process development. Traditional
methods like ion-exchange chromatography (IEX), often encounter
bottlenecks in method optimization, particularly when dealing with
complex molecules like enzymes, fusion proteins, and antibody-drug
conjugates (ADCs). MauriceFlex™, with the added capability of
protein charge fractionation, offers a tool that reduces several
pain points in charge species characterization, making it a routine
assay that can be performed at multiple stages of process
development.
During the WCBP conference, a presentation given by Xiaoping He and Sisi
Huang from Pfizer, demonstrated how MauriceFlex™ enabled the
characterization of charge species in AAV capsid proteins, helping
the acceleration of AAV gene therapy development. The second
presentation, by Qurrat (Anny) Ul-Ain and Zishuo (Toby) Cheng from Sanofi further showcased the
MauriceFlex system's efficiency in collecting multiple charge
variants of a complex protein with single-peak resolution for
downstream mass spectrometry characterization.
"The discussions at the conference, particularly regarding the
MauriceFlex™ system, reflect significant progress in the
advancements of analytical techniques used in biotherapeutic
development," said Will Geist,
President of Bio-Techne's Protein Sciences Segment. "These
developments underscore the need for continuous innovation around
analytical methods, empowering scientists to obtain critical
information they need to produce the best-in-class therapeutics for
patients worldwide".
About Bio-Techne Corporation (NASDAQ:TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/scientists-at-the-wcbp-conference-highlight-advancements-in-protein-biotherapeutic-charge-heterogeneity-characterization-using-the-mauriceflex-system-302042854.html
SOURCE Bio-Techne Corporation